title: [Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study].
abstract: OBJECTIVE
  The aim of this study was to assess renal and respiratory tolerance of aerosolized tobramycin in intubated and mechanically ventilated patients with nosocomial pneumonia.
  
  
  METHODS
  This was a multicenter, randomized, double-blind, placebo controlled study. Thirty-eight mechanically ventilated patients with documented nosocomial pneumonia were included. Patients treated with intravenous betalactam and tobramycin were randomly allocated to receive aerosolized tobramycin (6 mg/kg/day, n = 21) or placebo (n = 17). The aerosol was administered via a pneumatic nebulizer once a day for 5 days.
  
  
  RESULTS
  Respiratory tolerance was good in all but two patients. No acute renal failure occurred. By day 10, 7 patients in the tobramycin group (35%) had been extubated versus 3 in the placebo group (18.5%, p = 0.18). By day 28, 6 patients had died (2 in the tobramycin group and 4 in the placebo group, p = 0.23).
  
  
  CONCLUSIONS
  Aerosolized tobramycin was well tolerated in ventilated patients with documented nosocomial pneumonia.
authors.affiliation: Laboratoire d'Antibiologie Expérimentale, Faculté de médecine de Nantes. pleconte@sante.univ-nantes.fr
authors.forename: P
authors.initials: P
authors.lastname: Le Conte
authors.forename: G
authors.initials: G
authors.lastname: Potel
authors.forename: E
authors.initials: E
authors.lastname: Clémenti
authors.forename: A
authors.initials: A
authors.lastname: Legras
authors.forename: D
authors.initials: D
authors.lastname: Villers
authors.forename: E
authors.initials: E
authors.lastname: Bironneau
authors.forename: J
authors.initials: J
authors.lastname: Cousson
authors.forename: D
authors.initials: D
authors.lastname: Baron
mesh_terms: D000328:Adult; D000336:Aerosols; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003404:Creatinine / Q000097:blood; D003428:Cross Infection / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007442:Intubation, Intratracheal; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010919:Placebos; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D012119:Respiration / Q000187:drug effects; D012121:Respiration, Artificial; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000336:Aerosols; D000900:Anti-Bacterial Agents; D010919:Placebos; D003404:Creatinine; D014031:Tobramycin